The trial included patients diagnosed with CML or Philadelphia chromosome–positive acute lymphoblastic leukemia who had shown resistance or intolerance to dasatinib or nilotinib, or had a detectable BCR::ABL1 T315I mutation, regardless of prior TKI treatment.25 The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.